These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34832883)

  • 1. Model-Based Approach for Designing an Efficient Bioequivalence Study for Highly Variable Drugs.
    Song E; Lee W; Kim BH
    Pharmaceuticals (Basel); 2021 Oct; 14(11):. PubMed ID: 34832883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence.
    Tothfalusi L; Endrenyi L; Arieta AG
    Clin Pharmacokinet; 2009; 48(11):725-43. PubMed ID: 19817502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing for bioequivalence of highly variable drugs from TR-RT crossover designs with heterogeneous residual variances.
    Kang Q; Vahl CI
    Pharm Stat; 2017 Sep; 16(5):361-377. PubMed ID: 28620937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The bioequivalence of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consumer's risk in the EMA and FDA regulatory approaches for bioequivalence in highly variable drugs.
    Muñoz J; Alcaide D; Ocaña J
    Stat Med; 2016 May; 35(12):1933-43. PubMed ID: 26707698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-stage designs versus European scaled average designs in bioequivalence studies for highly variable drugs: Which to choose?
    Molins E; Cobo E; Ocaña J
    Stat Med; 2017 Dec; 36(30):4777-4788. PubMed ID: 28853164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Exact Procedure for the Evaluation of Reference-Scaled Average Bioequivalence.
    Tothfalusi L; Endrenyi L
    AAPS J; 2016 Mar; 18(2):476-89. PubMed ID: 26831249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of group sequential and fixed sample size designs for bioequivalence trials with highly variable drugs.
    Knahl SIE; Lang B; Fleischer F; Kieser M
    Eur J Clin Pharmacol; 2018 May; 74(5):549-559. PubMed ID: 29362819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
    Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
    PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence for highly variable drugs: regulatory agreements, disagreements, and harmonization.
    Endrenyi L; Tothfalusi L
    J Pharmacokinet Pharmacodyn; 2019 Apr; 46(2):117-126. PubMed ID: 30798390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample sizes for designing bioequivalence studies for highly variable drugs.
    Tothfalusi L; Endrenyi L
    J Pharm Pharm Sci; 2012; 15(1):73-84. PubMed ID: 22365089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PhRMA perspective on population and individual bioequivalence.
    Barrett JS; Batra V; Chow A; Cook J; Gould AL; Heller AH; Lo MW; Patterson SD; Smith BP; Stritar JA; Vega JM; Zariffa N
    J Clin Pharmacol; 2000 Jun; 40(6):561-70. PubMed ID: 10868305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interchangeability between Generic and Reference Products: Limits of Average Bioequivalence Methodology.
    Lechat P
    Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):777-787. PubMed ID: 35986193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflation of the type I error: investigations on regulatory recommendations for bioequivalence of highly variable drugs.
    Wonnemann M; Frömke C; Koch A
    Pharm Res; 2015 Jan; 32(1):135-43. PubMed ID: 25033764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Algorithms for evaluating reference scaled average bioequivalence: power, bias, and consumer risk.
    Tothfalusi L; Endrenyi L
    Stat Med; 2017 Nov; 36(27):4378-4390. PubMed ID: 28850696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Study to Compare Bioequivalence Approach Between FDA and EMA in a Highly Variable Drug: Pinaverium Bromide Film Tablets.
    Arısoy M; Saydam M; Ekin Dolaksız Y; Talay Ç; Sağlam O; Demiray G; Doğan Kurtoğlu E
    J Pharm Sci; 2022 Nov; 111(11):3149-3154. PubMed ID: 35981633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic bioequivalence testing.
    Li S
    J Clin Pharm Ther; 2012 Oct; 37(5):497-8. PubMed ID: 22428883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient model-based bioequivalence testing.
    Möllenhoff K; Loingeville F; Bertrand J; Nguyen TT; Sharan S; Zhao L; Fang L; Sun G; Grosser S; Mentré F; Dette H
    Biostatistics; 2022 Jan; 23(1):314-327. PubMed ID: 32696053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the leveling-off properties of the new bioequivalence limits for highly variable drugs of the EMA guideline.
    Karalis V; Symillides M; Macheras P
    Eur J Pharm Sci; 2011 Nov; 44(4):497-505. PubMed ID: 21945487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.